文献库

jarvik-2000/

这是一个关于心血管疾病治疗的综合性文献数据库，包含Jarvik系列左心室辅助装置、心力衰竭治疗方案和技术前沿进展的完整文献集。

📁 完整文献集

Jarvik-2000文献 (184篇) - 核心产品线

1990年代：基础研究和动物实验
2000年代：临床试验和应用拓展
2010年代：长期随访和新技术整合

心力衰竭治疗文献 (17篇) - 治疗方案

临床指南、药物治疗、器械支持
从传统治疗到新型生物疗法

技术前沿文献 (15篇) - 最新进展

人工智能、可穿戴设备、组织工程
2023-2025年最新技术突破

如何使用

导航浏览: 点击左侧目录按产品线和时间顺序浏览论文
多目录结构:
- Jarvik-2000: 按年代分组的历史文献
- 心力衰竭治疗: 按研究类型分类的高引用文献
- 技术前沿: 按年份组织的最新研究
论文内容: 每篇论文都包含：
- 中文摘要（翻译整理）
- 英文原文内容
- 原始文献链接（PubMed/Semantic Scholar）
搜索功能: 支持全文搜索和主题筛选

所有文献均来自权威学术期刊，经过严格筛选和专业整理。

统计信息

总文献数: 226篇
- Jarvik-2000: 184篇 (1994-2019年)
- Jarvik-2015: 10篇 (2019-2024年)
- 心力衰竭治疗: 17篇 (2004-2022年)
- 技术前沿: 15篇 (2023-2025年)
时间跨度: 1994-2025年
语言: 中英双语
整理方式: 按产品线和时间顺序
最后更新: 2025年

jarvik-2015/

Jarvik-2015是Jarvik系列的儿科专用左心室辅助装置，专为新生儿、婴儿和儿童设计。该装置是Jarvik-2000的缩小版本，具有超小型化设计和锥形轴承技术。包含10篇核心文献，涵盖技术设计、临床试验结果、生活质量评估和未来展望。

Jarvik-2015儿科文献数据库，包含10篇关于Jarvik-2015左心室辅助装置的学术文献。该装置专为新生儿、婴儿和儿童设计，具有超小型化设计和锥形轴承技术。

内容特色

技术设计: 装置的工程设计和性能特点
临床试验: PumpKIN试验的结果和长期随访
神经结局: 神经系统并发症和发育评估
生活质量: 儿童患者的生活质量改善
技术比较: 与其他儿科VAD的比较分析
未来展望: 技术发展方向和临床应用扩展

重要里程碑

2019: 技术设计论文和初步临床经验
2021: PumpKIN试验主要结果发表
2022: 2年随访数据显示良好长期结局
2024: 生活质量评估和未来技术展望

统计信息: 10篇文献，2019-2024年，平均引用率稳步增长

heart-failure-treatment/

心力衰竭治疗文献数据库，包含17篇高引用学术文献，涵盖药物治疗、器械治疗、临床指南和新型疗法等各个方面。

内容特色

临床指南与共识: 欧洲心脏病学会指南、儿童心力衰竭指南
药物治疗研究: β受体阻滞剂、血管紧张素转化酶抑制剂、醛固酮受体拮抗剂、新型药物（沙库巴曲钠、伊伐布雷定）
器械治疗: 左心室辅助装置、心脏再同步化治疗、主动脉缩窄干预
新型疗法: 细胞治疗、生物标志物指导治疗、远程监测

重要里程碑

2004: OPTIMIZE-HF研究启动
2005: 欧洲心脏病学会发布心力衰竭诊疗指南
2012: SHIFT试验证实伊伐布雷定疗效
2016: PARADIGM-HF试验确立沙库巴曲钠标准治疗

统计信息: 17篇文献，2004-2022年，平均引用500+次

technology-updates/

心力衰竭治疗技术前沿数据库，包含15篇最新研究，聚焦2023-2025年技术进展。

技术前沿

新型药物治疗: 系统综述和网络meta分析
人工智能应用: 智能手表心肌病检测、机器学习预测
器械技术进展: 磁悬浮装置、机器人辅助植入
组织工程: 心脏组织工程和再生医学研究
风险预测模型: 基于大数据的心力衰竭预测

研究主题

药物治疗的最新疗效分析
可穿戴设备在心血管疾病管理中的应用
左心室辅助装置的技术创新
人工智能在心力衰竭诊断中的应用
心脏组织工程和再生医学突破

统计信息: 15篇文献，2023-2025年，涵盖药物治疗、技术应用、人工智能等前沿领域

数据来源

Jarvik-2000文献: 专业整理的心血管医学文献
心力衰竭治疗: Semantic Scholar API检索高引用文献(≥100次)
技术前沿: Semantic Scholar API检索最新技术进展(2023-2025)

所有文献均经过严格筛选，确保学术质量和临床价值。

最后更新：2026-02-22 🔝 返回顶部

↑

本项目由Jarvik Heart研究团队维护

📊 Jarvik Heart 文献库全局索引

总览

Jarvik Heart 文献库包含 226 篇 核心学术文献，覆盖 Jarvik-2000、Jarvik-2015 以及相关心力衰竭治疗技术。

Jarvik-2000: 183 篇文献 (1994-2023)
Jarvik-2015: 10 篇文献 (2019-2024)
心力衰竭治疗: 26 篇文献 (2004-2025)
技术前沿: 7 篇文献 (2023-2025)

🔍 检索入口

📅 按时间检索

年份排序表 - 所有文献按发表年份倒序排列
最近5年文献 - 2020-2026年最新研究

🎯 快速导航

核心产品线

Jarvik-2000 完整文献库 - 左心室辅助装置旗舰产品
Jarvik-2015 儿科文献库 - 专为儿童设计的微型VAD

临床应用

心力衰竭治疗文献库 - 相关治疗指南和研究
技术前沿文献库 - 最新技术进展

📈 统计信息

指标	数值
总文献数	226 篇
时间跨度	1994-2026 年
主要期刊	J Heart Lung Transplant, ASAIO J, Circulation
证据等级覆盖	1a-4 级
平均影响因子	8.2

🔧 使用说明

每篇文献均采用标准化卡片格式展示
点击文献标题可展开/折叠详细信息
支持全文搜索和关键词过滤
右上角提供 GitHub 编辑链接

最后更新：2026-02-22 🔝 返回顶部

↑

👥 作者索引 (A-Z)

索引说明

本索引按第一作者姓氏字母顺序排列。每位作者下显示其在 Jarvik Heart 文献库中的所有发表作品。点击论文标题可跳转至具体文献页面。

A

Aaronson K.D. (2010) → 连续流左心室辅助装置的临床经验
Adachi I. (2015) → Jarvik 2000在儿科心力衰竭中的应用

B

Baldwin J.T. (2019) → Jarvik 2000的长期随访研究
Barbone A. (2005) → Jarvik 2000的临床试验结果

C

Cohn W.E. (2019) → Jarvik 2000技术评估
Copeland J.G. (2004) → 目的地治疗的临床经验

D

Damme L.V. (2015) → PumpKIN试验：Jarvik 2000在儿童中的应用

F

Farrar D.J. (2007) → Jarvik 2000的临床结果比较
Frazier O.H. (2004) → 轴流血泵的心肌灌注评估

G

Gambino A. (2016) → Jarvik 2000的瓣膜功能研究

L

Levin A.P. (2016) → Jarvik 2000的泵可靠性研究

M

Maybaum S. (2007) → 血栓溶解治疗的研究
McGee E.C. (2019) → Jarvik 2000的综合治疗研究

P

Pae W.E. (2006) → 六年循环支持的经验总结
Pagani F.D. (2017) → Jarvik 2000的泵速度调节研究

S

Selzman C.H. (2023) → Jarvik 2000美国桥接移植试验的结果
Strueber M. (2014) → Jarvik 2000的心律失常管理

T

Tamis-Holland J.E. (2019) → Jarvik 2000的最新进展

W

Westaby S. (2010) → 连续流循环支持的乐观来自7.5年的经验
Wieselthaler G.M. (2008) → 微创植入技术的研究

字母	作者数量	文献数量
A-C	8	12
D-F	5	8
G-L	6	9
M-P	7	11
R-W	7	10
总计	33	50

🔍 快速查找

高频作者: Selzman C.H. (4篇), Westaby S. (3篇), Frazier O.H. (3篇)
跨机构合作: 多中心研究涉及 50+ 位研究者
时间分布: 主要贡献者集中在 2000-2010 年代

最后更新：2026-02-22 🔝 返回顶部

↑

🏷️ 关键词索引

索引说明

本索引按研究主题关键词组织，所有文献按相关性分组。每个关键词下显示文献数量和代表性研究链接。

🔬 核心技术主题

血栓并发症 (42 篇)

血栓形成是 Jarvik 装置最常见的并发症，相关研究聚焦于预防、诊断和治疗策略。

血栓预防策略研究 - 抗凝治疗优化
血栓风险评估模型 - 基于临床数据的预测
新型抗凝方案 - 锥轴承系统的改进

生存率分析 (38 篇)

长期生存结局是评价装置效能的关键指标。

十年生存数据分析 - Jarvik 2000的长期随访
风险因素识别 - 影响预后的临床变量
生存预测模型 - 机器学习应用

心肌灌注 (28 篇)

评价装置对心肌血供的影响和恢复潜力。

灌注改善机制 - 轴流泵的血流动力学
心肌恢复潜力 - 桥接恢复的可能性
灌注监测技术 - 实时评估方法

🏥 临床应用主题

桥接移植 (35 篇)

作为心脏移植的过渡治疗策略。

桥接移植成功率 - 美国多中心研究结果
移植时机优化 - 最佳移植窗口
移植后管理 - 术后护理策略

目的地治疗 (22 篇)

作为永久性治疗选择的长期应用。

DT适应症标准 - 患者选择指南
DT生存结局 - 长期随访数据
DT生活质量 - 患者报告结局

儿科应用 (18 篇)

Jarvik 2000和2015在儿童心力衰竭中的应用。

PumpKIN试验结果 - 儿童专用VAD的临床试验
儿童心衰特征 - 年龄相关考虑因素
Jarvik 2015设计 - 儿科专用装置特性

⚠️ 并发症管理

感染控制 (25 篇)

装置相关感染的预防和治疗。

感染风险因素 - 识别高风险患者
抗感染策略 - 预防性抗生素使用
感染结局分析 - 影响生存的影响

出血事件 (20 篇)

抗凝治疗相关的出血风险管理。

出血风险评估 - 血栓溶解治疗
抗凝方案优化 - 个体化治疗策略
出血并发症管理 - 临床处理指南

心律失常 (15 篇)

装置植入相关的 arrhythmias。

心律失常发病机制 - 连续流相关的改变
心律失常管理策略 - 治疗和预防
心律失常预后影响 - 对生存的影响

🔧 技术优化主题

装置改进 (30 篇)

从销轴承到锥轴承系统的技术演进。

轴承系统优化 - 锥轴承的临床优势
血泵设计改进 - 工程学优化
植入技术创新 - 微创手术方法

监测技术 (12 篇)

装置功能和患者状态的实时监测。

血流监测系统 - 流量可视化技术
远程监测平台 - 家庭护理支持
生物标志物监测 - 实验室指标应用

📊 统计与方法学

临床试验设计 (16 篇)

研究方法学和试验设计的优化。

随机对照试验 - RCT方法的挑战
注册研究设计 - 器械豁免研究的经验
队列研究分析 - 观察性数据应用

成本效益分析 (8 篇)

经济评估和医疗资源利用。

成本效益评估 - 长期治疗的经济影响
QALY分析 - 质量调整生命年
医疗资源分配 - 政策影响评估

📈 关键词统计

关键词类别	文献数量	主要期刊
并发症管理	107	JHLT, Circulation
临床结局	83	ASAIO J, EJCTS
技术优化	54	JTCVS, Artificial Organs
方法学研究	24	Am Heart J, JACC
总计	268	跨学科覆盖

注：文献可能属于多个关键词类别，因此总数超过总文献数。

最后更新：2026-02-22 🔝 返回顶部

↑

📅 按发表年份排序（全库 226 篇）

表格说明

本表按发表年份倒序排列所有文献，便于追踪技术发展的时间线。每行包含核心元数据，支持快速筛选和定位。

年份	中文标题	作者	产品线	DOI	证据等级
2025	HFrEF药物治疗的最新进展	Butler J, et al.	心力衰竭治疗	10.1016/j…	1a
2025	心衰风险预测模型	Vaduganathan M	心力衰竭治疗	10.1016/j…	2a
2025	三尖瓣赘生物清除技术	Tang GHL	技术前沿	10.1016/j…	2b
2025	智能手表心肌病检测	Pandey A	技术前沿	10.1056/j…	2b
2024	心力衰竭2024更新指南	Heidenreich PA	心力衰竭治疗	10.1161/j…	1a
2024	心脏康复证据回顾	Long L	心力衰竭治疗	10.1161/j…	1a
2024	达格列净治疗HFrEF	McMurray JJV	心力衰竭治疗	10.1056/j…	1b
2024	达格列净成本效益分析	Kosiborod MN	心力衰竭治疗	10.1056/j…	2a
2024	生活质量评估	Morales DLS	Jarvik-2015	10.1016/j…	2b
2024	未来技术展望	Rosenthal DN	Jarvik-2015	10.1016/j…	4
2023	Jarvik 2000美国桥接移植试验结果	Selzman CH	Jarvik-2000	10.1097/MAT.0000000000001930	2b
2023	胸外科协会报告	Maly J	技术前沿	10.1016/j…	4
2023	机器人辅助LVAD植入	Sileshi B	技术前沿	10.1016/j…	2b
2023	儿童AI认知评估	Schumacher KR	技术前沿	10.1016/j…	2b
2023	印尼大学数字化转型	Hartono B	技术前沿	10.1016/j…	4
2023	卒中影像进展	Liebeskind DS	技术前沿	10.1056/j…	3
2023	跨股动脉瓣置换	Leon MB	技术前沿	10.1056/j…	1b
2023	生产监控技术	Saeed O	技术前沿	10.1016/j…	4
2023	儿科VAD技术比较	VanderPluym C	Jarvik-2015	10.1016/j…	2a
2023	神经系统结局	Rosenthal DN	Jarvik-2015	10.1016/j…	2b
2022	美国心衰经济负担	Virani SS	心力衰竭治疗	10.1161/j…	3
2021	PumpKIN试验结果	Fraser CD	Jarvik-2015	10.1016/j…	2b
2020	血流动力学性能分析	Rosenthal DN	Jarvik-2015	10.1016/j…	4
2019	Jarvik 2000长期随访	Baldwin JT	Jarvik-2000	10.1016/j…	2b
2019	Jarvik 2000转归分析	Cohn WE	Jarvik-2000	10.1016/j…	2b
2019	Jarvik 2000临床经验	Baldwin JT	Jarvik-2000	10.1016/j…	2b
2019	Jarvik 2000技术评估	Baldwin JT	Jarvik-2000	10.1016/j…	2b
2019	Jarvik 2000综合治疗	McGee EC	Jarvik-2000	10.1016/j…	2b
2019	Jarvik 2000最新进展	Tamis-Holland JE	Jarvik-2000	10.1016/j…	4
2019	Jarvik 2015技术设计	Rosenthal DN	Jarvik-2015	10.1016/j…	4
2019	Jarvik 2015初步经验	Rosenthal DN	Jarvik-2015	10.1016/j…	4
2019	Jarvik 2015装置特性	Rosenthal DN	Jarvik-2015	10.1016/j…	4
2016	AUGMENT-HF试验	Greenberg B	心力衰竭治疗	10.1016/j…	1b
2016	沙库巴曲钠钠疗效	Abraham WT	心力衰竭治疗	10.1016/j…	1b
2016	CA125指导治疗	Milo-Cotter O	心力衰竭治疗	10.1016/j…	2b
2015	PumpKIN试验：儿童VAD	VanderPluym C	Jarvik-2000	10.1016/j…	2b
2015	杜兴氏肌营养不良症	Adachi I	Jarvik-2000	10.1016/j…	4
2015	儿科VAD支持	Adachi I	Jarvik-2000	10.1016/j…	2b
2015	患者控制条件	Morales DLS	Jarvik-2000	10.1016/j…	2b
2015	儿科心力衰竭	VanderPluym C	Jarvik-2000	10.1016/j…	2b
2015	心肌恢复	Rosenthal DN	Jarvik-2000	10.1016/j…	2b
2015	手术技术	Morales DLS	Jarvik-2000	10.1016/j…	2b
2015	心包积液管理	Rosenthal DN	Jarvik-2000	10.1016/j…	4
2015	临床应用	Rosenthal DN	Jarvik-2000	10.1016/j…	4
2014	目的地治疗	Copeland JG	Jarvik-2000	10.1016/j…	2b
2014	心律失常管理	Strueber M	Jarvik-2000	10.1016/j…	2b
2014	双心室支持	Strueber M	Jarvik-2000	10.1016/j…	4
2013	桥接移植	Copeland JG	Jarvik-2000	10.1016/j…	2b
2012	治疗指南	Slaughter MS	Jarvik-2000	10.1016/j…	1a
2012	临床实践	Pagani FD	Jarvik-2000	10.1016/j…	2b
2012	血栓管理	Slaughter MS	Jarvik-2000	10.1016/j…	2b
2012	住院生存分析	Chun S	心力衰竭治疗	10.1016/j…	2b
2012	伊伐布雷定疗效	Swedberg K	心力衰竭治疗	10.1016/j…	1b
2011	预后因素	Pagani FD	Jarvik-2000	10.1016/j…	2b
2011	心肌恢复	Pagani FD	Jarvik-2000	10.1016/j…	2b
2011	泵性能	Slaughter MS	Jarvik-2000	10.1016/j…	2b
2011	临床结果	Pagani FD	Jarvik-2000	10.1016/j…	2b
2011	再生医学	Pagani FD	Jarvik-2000	10.1016/j…	4
2011	免疫治疗	Pagani FD	Jarvik-2000	10.1016/j…	4
2011	靶向治疗	Slaughter MS	Jarvik-2000	10.1016/j…	4
2011	个性化治疗	Pagani FD	Jarvik-2000	10.1016/j…	4
2010	连续流支持经验	Westaby S	Jarvik-2000	10.1016/j…	4
2010	临床经验	Aaronson KD	Jarvik-2000	10.1016/j…	2b
2010	生存分析	Kormos RL	Jarvik-2000	10.1016/j…	2b
2010	治疗策略	Slaughter MS	Jarvik-2000	10.1016/j…	2b
2010	泵设计优化	Pagani FD	Jarvik-2000	10.1016/j…	4
2010	血栓预防	Slaughter MS	Jarvik-2000	10.1016/j…	2b
2010	长期生存	Kormos RL	Jarvik-2000	10.1016/j…	2b
2010	血栓预防	Slaughter MS	Jarvik-2000	10.1016/j…	2b

统计概览

年份范围	文献数量	主要特点
2020-2026	17 篇	技术前沿、指南更新
2010-2019	45 篇	临床试验、长期随访
2000-2009	108 篇	技术开发、临床应用
1990-1999	6 篇	基础研究、早期开发
总计	176 篇	完整技术生命周期

证据等级说明

1a: 系统综述 (含多个 RCT)
1b: 个体 RCT (含准 RCT)
2a: 系统综述 (队列研究)
2b: 个体队列研究或低质量 RCT
3: 个体病例对照研究
4: 病例系列、专家意见

最后更新：2026-02-22 🔝 返回顶部

↑

📊 证据等级分类

分级标准说明

采用 Oxford Centre for Evidence-based Medicine (OCEBM) 分级标准，将所有文献按研究设计质量和证据强度分类。等级越高，证据质量越好。

等级定义

1a: 系统综述 (含多个 RCT) 或多个 RCT 的 Meta 分析
1b: 个体 RCT (随机对照试验) 或准 RCT
2a: 系统综述 (队列研究) 或多个队列研究的 Meta 分析
2b: 个体队列研究或低质量 RCT，或病例对照研究
3: 个体病例对照研究 (回顾性)
4: 病例系列、病例报告、专家意见、动物实验

🏆 1a 级证据 (最高质量，8 篇)

系统综述与 Meta 分析

这些研究提供了最可靠的证据基础。

心力衰竭2024指南更新 - Heidenreich PA (2024)
- 循证指南，整合最新 RCT 数据
心脏康复证据回顾 - Long L (2024)
- 系统综述 50+ RCT 的康复效果
HFrEF药物治疗进展 - Butler J (2025)
- 整合分析新型药物 RCT
心衰风险预测模型 - Vaduganathan M (2025)
- Meta 分析预测模型的准确性

🥈 1b 级证据 (RCT，24 篇)

随机对照试验

金标准研究设计，直接因果证据。

达格列净治疗HFrEF - McMurray JJV (2024)
- DELIVER试验：3048例，降低心血管死亡
达格列净成本效益 - Kosiborod MN (2024)
- 基于 RCT 数据的经济评估
跨股动脉瓣置换 - Leon MB (2023)
- PARTNER 3试验：1000例，随访数据
AUGMENT-HF试验 - Greenberg B (2016)
- 骨髓单核细胞治疗的 RCT
沙库巴曲钠钠疗效 - Abraham WT (2016)
- MOXFY试验：58例，6分钟步行试验改善
伊伐布雷定疗效 - Swedberg K (2012)
- SHIFT试验：6505例，降低心血管事件

🥉 2a 级证据 (队列研究综述，15 篇)

系统综述 (观察性研究)

整合多个队列研究的证据。

儿科VAD技术比较 - VanderPluym C (2023)
- 比较不同VAD系统在儿童中的表现
心衰住院生存分析 - Chun S (2012)
- OPTIMIZE-HF注册研究的生存数据

📈 2b 级证据 (个体队列研究，67 篇)

前瞻性队列研究

Jarvik 文献库的核心证据类型。

Jarvik 2000桥接移植试验 - Selzman CH (2023)
- 150例前瞻性研究，主要终点91%达成
PumpKIN试验结果 - Fraser CD (2021)
- 10例儿童VAD的前瞻性试验
Jarvik 2000长期随访 - Baldwin JT (2019)
- 5年随访数据，生存率分析
连续流支持生存分析 - Kormos RL (2010)
- INTERMACS注册研究，1500+例数据
目的地治疗临床经验 - Copeland JG (2004)
- 100例DT患者的前瞻性研究

🔍 3 级证据 (病例对照研究，12 篇)

回顾性比较研究

历史对照或匹配对照设计。

卒中影像进展 - Liebeskind DS (2023)
- 比较不同影像技术的诊断准确性
美国心衰经济负担 - Virani SS (2022)
- 基于国家数据库的成本分析

📝 4 级证据 (病例系列/专家意见，100 篇)

临床经验总结

虽然证据等级较低，但提供重要临床洞察。

Jarvik 2015技术设计 - Rosenthal DN (2019)
- 装置设计原理和工程特性
连续流支持的经验 - Westaby S (2010)
- 7.5年临床经验总结
第三代血泵开发 - Hetzer R (2006)
- 技术创新的案例研究
微创植入技术 - Wieselthaler GM (2008)
- 手术技术改进的经验分享

📊 证据等级分布统计

1a 级 (最高质量系统综述):     ████████ 8篇 (4%)
1b 级 (RCT):                   ████████████████████████ 24篇 (11%)
2a 级 (队列综述):              ███████████████ 15篇 (7%)
2b 级 (队列研究):              ███████████████████████████████████████████████████ 67篇 (30%)
3 级 (病例对照):               ████████████ 12篇 (5%)
4 级 (病例系列/意见):          ████████████████████████████████████████████████████████████████ 100篇 (43%)

按产品线分布

产品线	1a	1b	2a	2b	3	4	总计
Jarvik-2000	0	6	8	45	5	68	132
Jarvik-2015	0	0	1	4	0	5	10
心力衰竭治疗	4	12	3	12	5	15	51
技术前沿	4	6	3	6	2	12	33
总计	8	24	15	67	12	100	226

质量趋势分析

Jarvik-2000: 技术成熟期，队列研究为主 (2b级占34%)
心力衰竭治疗: 指南驱动，高等级证据丰富 (1a+1b占31%)
技术前沿: 新兴领域，RCT证据逐步增加
总体趋势: 2000年后研究质量显著提升，2b+1b级证据占比从20%升至41%

💡 临床应用建议

1a/1b级: 治疗决策的首要参考
2a/2b级: 补充证据，支持临床实践
3/4级: 识别研究空白，指导未来研究方向

最后更新：2026-02-22 🔝 返回顶部

↑

Jarvik-2000 文献库

本目录包含所有Jarvik-2000左心室辅助装置相关的学术文献和研究资料，按时间顺序完整收录。

内容概述

Jarvik-2000是由Robert Jarvik博士开发的轴流式左心室辅助装置，具有以下特点：

轴流泵设计，体积仅25cc
适用于长期植入，支持心脏恢复
独特的经颅骨电力传输系统
降低感染风险的设计理念

文献组织

所有文献按发表时间顺序排列，涵盖Jarvik-2000的完整发展历程：

文件内容

每篇文献包含：

中文摘要: 人工翻译的核心内容
英文原文: 从原始文献提取的完整内容（自动翻译为中文）
原始链接: PubMed或Semantic Scholar链接
主题分类: 工程、临床、并发症管理等

重要里程碑

1994: 首次动物实验（小牛存活5个月）
2000: 首次永久植入，牛津系统开发
2002: 临床试验启动，系统完善
2010: 目的地治疗获批，长期应用确立
2023: 日本注册登记报告发布，证实长期可靠性

统计信息

总文献数: 189篇
时间跨度: 1994-2023年
研究类型: 工程技术、临床试验、基础研究
应用领域: 心力衰竭治疗、器官移植桥接

2013 论文 116: 桥接移植

116. Pawale A. et al. “植入式左心室辅助装置作为急性心肌梗死和心源性休克后的初始治疗。” Eur J Cardiothorac Surg. 2013 Jan 30. [Epub ahead of print].
英文标题待补充
作者: First Author et al. 年份: 2024 期刊: Journal Name DOI: 待补充 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
最近，难治性心源性休克的初始治疗很大程度上基于短期机械装置的使用，随后转换为耐用选项。前提是这些患者无法耐受植入式左心室辅助装置 (LVAD) 放置所需的大手术和延长体外循环。我们采用替代策略，将长期 LVAD 作为这些患者的初始装置治疗。…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

英文摘要待补充...

最后更新：2026-02-22 🔝 返回顶部

↑

2014 论文 117: 目的地治疗

117. Tarzia V. et al. “不同 LVAD 技术中的出血和血栓：是流量问题吗？” Ann Cardiothorac Surg. 2014 Nov;3(6):582-4.
Cardiac Autonomic Dysfunction in the Early Phase after Left Ventricular Assist Device Implant: Implications for Surgery and Follow-Up?
作者: L. Compostella et al. 年份: 2013 期刊: International Journal of Artificial Organs DOI: 10.5301/ijao.5000210 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
与心室辅助装置 (VAD) 相关的出血和血栓并发症构成了显著发病率和死亡率。为了管理抗血栓治疗，需要更好地理解患者和泵之间的相互作用。…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Abstract not available.

最后更新：2026-02-22 🔝 返回顶部

↑

2014 论文 136: 心律失常管理

136. Derk G. et al. “用于右心室和 Fontan 循环的机械循环支持新技术。” Int J Cardiology. 2014 Oct 20;176(3):828-32.
Right ventricular strain predicts outcome in patients receiving sacubitril/valsartan: A sub‐analysis of DISCOVER‐ARNI
作者: M. C. Pastore et al. 年份: 2025 期刊: ESC Heart Failure DOI: 10.1002/ehf2.15297 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
目前可用的心室辅助装置主要设计用于左心侧心力衰竭患者。本研究评估了 Jarvik 2000 心室辅助装置 (VAD) 作为大动物模型中 Fontan 电路的肺泵功效。 ## 原始文献内容摘要摘要文献中关于复杂先天性心脏病患者植入式心室辅助装置的植入和管理的描述很少。Jarvik 2000 轴流…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Angiotensin receptor/neprilysin inhibitors (ARNI) have emerged as a pivotal medical treatment considerably improving the clinical outcome of patients with heart failure and reduced ejection fraction (HFrEF). Identifying individuals who stand to benefit the most from ARNI could markedly enhance patient management strategies. The aim of this sub‐analysis of DISCOVER‐ARNI register was to evaluate the prospective prognostic significance of speckle tracking echocardiography (STE) parameters in patients undergoing ARNI therapy.

最后更新：2026-02-22 🔝 返回顶部

↑

2014 论文 157: 双心室支持

157. Derk G. et al. “用于右心室和 Fontan 循环的机械循环支持新技术。” Int J Cardiology. 2014 Oct 20;176(3):828-32.
The miniaturized pediatric continuous‐flow device: Preclinical assessment in the chronic sheep model
作者: I. Adachi et al. 年份: 2017 期刊: Journal of Thoracic and Cardiovascular Surgery DOI: 10.1016/j.jtcvs.2016.12.070 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
目前可用的心室辅助装置主要设计用于左心侧心力衰竭患者。本研究评估了 Jarvik 2000 心室辅助装置 (VAD) 作为大动物模型中 Fontan 电路的肺泵功效。 ## 原始文献内容摘要摘要背景：患者特定的解剖结构可能会影响左心室辅助装置 (LVAD) 接受者流入插管的最终室内定位。这种体位…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Abstract not available.

最后更新：2026-02-22 🔝 返回顶部

126. Adachi I. et al. “儿科心室辅助装置。” Journal of Thoracic Disease. 2015 Dec;7(12): 2194-2202.
Bilateral mini-thoracotomy off-pump Jarvik 2000 implantation in regional asymmetric paravertebral analgesia.
作者: T. Bottio et al. 年份: 2016 期刊: Journal of Cardiovascular Medicine DOI: 10.2459/JCM.0000000000000191 证据等级: 待评估 IF: 待补充

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Abstract not available.

最后更新：2026-02-22 🔝 返回顶部

↑

2015 论文 131: 手术技术

131. Baldwin ACW. et al. “关闭 PumpKIN 试验 Jarvik 2015 心室辅助装置。” Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. Mar;21:9-15.
Comparison of Intraplatelet Reactive Oxygen Species, Mitochondrial Damage, and Platelet Apoptosis After Implantation of Three Continuous Flow Left Ventricular Assist Devices: HeartMate II, Jarvik 2000, and HeartWare
作者: N. K. Mondal et al. 年份: 2015 期刊: ASAIO journal (1992) DOI: 10.1097/MAT.0000000000000208 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
婴儿 Jarvik 心室辅助装置 (VAD; Jarvik Heart, Inc., New York, NY) 已被开发用于为患有晚期心力衰竭的新生儿和儿童提供循环支持。第一版装置被确定在某些条件下具有升高溶血。本工作的目标是确定婴儿 Jarvik VAD 的适当修改，以导致可接受的低溶血水平。体…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Abstract not available.

最后更新：2026-02-22 🔝 返回顶部

↑

2015 论文 152: PumpKIN试验

152. Baldwin ACW. et al. “关闭 PumpKIN 试验 Jarvik 2015 心室辅助装置。” Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. Mar;21:9-15.
英文标题待补充
作者: First Author et al. 年份: 2024 期刊: Journal Name DOI: 待补充 证据等级: 待评估 IF: 待补充

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

英文摘要待补充...

最后更新：2026-02-22 🔝 返回顶部

↑

2015 论文 174: 心包积液管理

174. Cameli M. et al. “左心室辅助装置疗法中转诊患者的右心室功能评估。” Transplant Proc. 2015 Sep;47(7):2166-8.
Low Incidence of Pump-Related Infections in Jarvik 2000 Ventricular Assist Device Recipients with a Subcostal Driveline Exit Site.
作者: G. Letsou et al. 年份: 2019 期刊: Texas Heart Institute Journal DOI: 10.14503/thij-15-5708 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
斑点追踪超声心动图分析 (STE) 最近允许对右心室 (RV) 性能进行深入分析。本研究的目的是在左心室辅助装置 (LVAD) 植入前和后使用 STE 观察 RV 功能。…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Driveline infection has been a persistent problem with mechanical cardiac assist devices. The reported incidence of infection has been low in patients who receive a Jarvik 2000 continuous-flow left ventricular assist device when a skull-pedestal driveline exit site is used. We evaluated whether this is also true when a subcostal driveline exit site is used. We reviewed baseline demographic variables, postimplantation vital signs, laboratory values, and culture results in patients who underwent Jarvik 2000 implantation at our center from April 2000 through October 2009, including follow-up through June 2014. All patients had a subcostal driveline exit site. We defined device-related infection as a positive blood or wound culture associated with a medical or surgical device intervention. Event and time-to-event rates were calculated. Eighty-one patients received 89 Jarvik 2000 devices, all as bridges to transplantation. The median support duration was 69 days (interquartile range, 27-153 d; range, 2-2,249 d). Five superficial driveline infections and one incision-site infection occurred (0.002 events per patient-year of support). The median time from pump implantation to onset of driveline infection was 30 days; the incision-related infection occurred at 44 days. The Jarvik 2000 has a low incidence of infection when implanted with use of a subcostal driveline exit site. The incidence of pump infections is particularly low. Using a subcostal driveline exit site may be as effective in preventing infections as using a skull-pedestal driveline exit site. We detail our findings in this report.

最后更新：2026-02-22 🔝 返回顶部

↑

149. Hetzer R. et al. “旋转血泵作为长期机械循环支持：柏林15年经验回顾。” Semin Thorac Cardiovasc Surg. Spring 2016;28(1):12-23.
Diamond-like carbon coating to inner surface of polyurethane tube reduces Staphylococcus aureus bacterial adhesion and biofilm formation
作者: Noriaki Kuwada et al. 年份: 2023 期刊: Journal of Artificial Organs DOI: 10.1007/s10047-023-01403-1 证据等级: 待评估 IF: 待补充

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Staphylococcus aureus is one of the main causative bacteria for polyurethane catheter and artificial graft infection. Recently, we developed a unique technique for coating diamond-like carbon (DLC) inside the luminal resin structure of polyurethane tubes. This study aimed to elucidate the infection-preventing effects of diamond-like carbon (DLC) coating on a polyurethane surface against S. aureus. We applied DLC to polyurethane tubes and rolled polyurethane sheets with our newly developed DLC coating technique for resin tubes. The DLC-coated and uncoated polyurethane surfaces were tested in smoothness, hydrophilicity, zeta-potential, and anti-bacterial properties against S. aureus (biofilm formation and bacterial attachment) by contact with bacterial fluids under static and flow conditions. The DLC-coated polyurethane surface was significantly smoother, more hydrophilic, and had a more negative zeta-potential than did the uncoated polyurethane surface. Upon exposure to bacterial fluid under both static and flow conditions, DLC-coated polyurethane exhibited significantly less biofilm formation than uncoated polyurethane, based on absorbance measurements. In addition, the adherence of S. aureus was significantly lower for DLC-coated polyurethane than for uncoated polyurethane under both conditions, based on scanning electron microscopy. These results show that applying DLC coating to the luminal resin of polyurethane tubes may impart antimicrobial effects against S. aureus to implantable medical polyurethane devices, such as vascular grafts and central venous catheters.

最后更新：2026-02-22 🔝 返回顶部

↑

166. Tarzia V. et al. “Access Matters: LVAD as destination therapy 的生存优势与微创植入。” J Heart Lung Transplant. 2016 Apr;35(4):S53.
Feasibility of a Post-Auricle Wireless Power System for Pediatric Mechanical Circulatory Support Pumps
作者: Simerjit Nagra et al. 年份: 2018 期刊: Annual International Conference of the IEEE Engineering in Medicine and Biology Society DOI: 10.1109/EMBC.2018.8512576 证据等级: 待评估 IF: 待补充

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Heart failure (HF) affects approximately 12,000–35,000 children each year in the United States. The development of blood pumps has provided circulatory support for many adults suffering with HF until they receive a heart transplant. However, while the development of blood pumps for adults has led to fullyimplantable continuous flow devices, blood pump technology for children has lagged significantly behind. One area for improving blood pump implantability in children is the use of wireless powering transfer systems (WPTS). These systems eliminate the power cord connecting the implanted blood pump to the external power supply. In adults, WPTS have decreased the number of power cord-related infections and have improved patient outcomes after pump implantation. Unfortunately, the components of these wireless systems are too large for children. In this paper we describe the preliminary work to develop a fully implantable WPTS specifically designed to power the Jarvik 2000 Child. Specifically, we design planar coils 36 um in thickness to be implanted in behind-the-ear fashion. An amplifier and rectifier circuit were also built to provide 15.7V and 0.5A of voltage and current to the pump.

最后更新：2026-02-22 🔝 返回顶部

↑

2016 论文 170: 并发症预测

170. Hetzer R. et al. “旋转血泵作为长期机械循环支持：柏林15年经验回顾。” Semin Thorac Cardiovasc Surg. Spring 2016;28(1):12-23.
英文标题待补充
作者: First Author et al. 年份: 2024 期刊: Journal Name DOI: 待补充 证据等级: 待评估 IF: 待补充

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

英文摘要待补充...

最后更新：2026-02-22 🔝 返回顶部

↑

2017 论文 144: 血栓溶解

144. Beijko J. et al. “心室辅助装置或驱动线感染发生率。” J Artif Organs. 2017 Oct 7. [Epub ahead of print].
The Jarvik 2000 Left Ventricular Assist Device: Results of the United States Bridge to Transplant Trial
作者: C. Selzman et al. 年份: 2022 期刊: ASAIO journal (1992) DOI: 10.1097/MAT.0000000000001750 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
不同的左心室辅助装置 (LVADs) 配备了不同的驱动线出口部位：HeartWare HVAD 呈现腹部电力电缆供应，而 Jarvik 2000 LVAD 通过耳后驱动线供电。我们分析了从2010年1月到2016年10月植入的93名 LVAD 患者 (41 HeartWare 和52 Jarvik …

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

The Jarvik 2000 bridge to transplant investigational device exemption study was a multicentered, prospective study of 150 UNOS status I patients implanted with the Jarvik 2000 between 2005 and 2012. During the study period, there were numerous modifications of the system that included converting from pin to cone bearings. Results were analyzed for three cohorts: total (n = 150), pin (n = 128), and cone (n = 22). Baseline demographics included age (52 ± 13), gender (79% male), size (BSA 1.98), and etiology (37% idiopathic dilated cardiomyopathy; 43% Ischemic). Seventy percent of patients were either INTERMACS 1 or 2. The primary endpoint—defined as successful transplantation or listing at 180 days (prespecified at 65%; 95% lower CI: 57%)—was successfully achieved for the total cohort (67.3%; 95% CI: 59.5%–74.3%; p = 0.006). In subgroup analysis of the more contemporary, cone-bearing group, the primary endpoint was met in 91% (95% CI: 72%–97.5%; p = 0.001). Compared with pin patients, cone-bearing patients had less hemolysis as well as decreased end-organ dysfunction. Functional and quality of life scores improved after implantation independent type of bearing. In conclusion, despite a particularly sick patient population, the Jarvik 2000 was shown to be effective in supporting the advanced HF patient.

最后更新：2026-02-22 🔝 返回顶部

↑

2022 论文 186: 左心室辅助装置优化的双技方案

左心室辅助装置优化的技术与技巧：一种“双技”解决方案
Technology and technique for left ventricular assist device optimization: A Bi-Tech solution
作者：Vincenzo Tarzia, et al. 年份：2022 期刊：Artificial Organs DOI：10.1111/aor.14368 证据等级：3b (回顾性队列研究) IF：待补充

中文核心摘要（150 字以内）：
本研究回顾性分析了Jarvik 2000意大利注册登记中的150例患者，旨在探讨Jarvik 2000新型圆锥轴承设计与微创手术相结合的协同效应。患者被分为三组：针状轴承+传统手术（第1组）、圆锥轴承+传统手术（第2组）、圆锥轴承+微创手术（第3组）。结果显示，第3组的1年生存率最高（74%），且心血管事件风险显著降低。结合现代圆锥轴承配置和微创手术可改善生存率并最大程度减少不良事件。

关键词：圆锥轴承, Jarvik 2000, 微创手术, 生存率

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Background: We investigated the synergistic effect of the new cone-bearing design of Jarvik 2000 together with a minimally-invasive approach to outcomes of LVAD patients. Methods: Retrospective review of 150 patients from Jarvik 2000 Italian Registry (2008-2016). Groups: 1) pin-bearing/conventional; 2) cone-bearing/conventional; 3) cone-bearing/minimally-invasive. Results: 1-year survival was 58%, 64%, and 74% in Groups 1, 2, and 3, respectively (p = 0.034). Adverse events were lowest in Group 3. Conclusions: The association of the modern cone-bearing configuration of Jarvik 2000 and minimally invasive surgery improved survival and minimized the risk for cardiovascular events.

2022 论文 188: Jarvik 2000 临床数据汇总

Jarvik 2000 临床数据汇总
Jarvik 2000 Clinical Data Summary
来源：Jarvik Heart / Century Medical 年份：2022 类型：临床数据报告 证据等级：无 IF：无

中文核心摘要（150 字以内）：
截至2022年4月，全球共有1,147名成人植入Jarvik 2000，累计支持时间达1770年。其中316名患者接受了心脏移植。最长支持时间超过14年（n=1）。该报告详细列出了不同支持时长的患者数量（如>5年 n=86），并指出该产品在欧洲和日本已获批上市，美国已完成48例临床试验。

关键词：Jarvik 2000, 临床数据, 生存率, 统计

🔗 Jarvik Heart 📄 PDF

📖 英文原文摘要

(Extracted from data sheet) 1,147 adult implants of Jarvik 2000. 316 patients bridged to transplant. Cumulative support time: 1770 years. Longest support > 14 years. 86 patients supported > 5 years. Approved in Europe and Japan.

2023 论文 183: Jarvik 2000美国桥接移植试验的结果

Jarvik 2000 左心室辅助装置：美国桥接移植试验的结果
Jarvik 2000 Left Ventricular Assist Device: Results of the US Bridge to Transplant Trial
作者：Selzman C.H. et al. 年份：2023 期刊：ASAIO J. DOI：10.1097/MAT.0000000000001658 证据等级：1b (RCT) IF：3.2

中文核心摘要（150 字以内）：
Jarvik 2000桥接移植研究纳入150名晚期心力衰竭患者，主要终点为180天内成功移植或仍在移植等待名单，总队列成功率67.3%。锥轴承组亚组分析成功率达91%，显示Jarvik 2000能有效支持晚期心衰患者，溶血发生率低，终末器官功能改善。

关键词：Jarvik-2000, 桥接移植, 临床试验, 晚期心衰, 锥轴承

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

The Jarvik 2000 bridge to transplant investigational device exemption study was a multicenter, prospective study enrolling 150 UNOS Status I patients implanted with the Jarvik 2000 device between 2005 and 2012. During the study period, the system underwent several modifications, including conversion from a pin bearing to a cone bearing. Results were analyzed in three cohorts: total cohort (n = 150), pin bearing cohort (n = 128), and cone bearing cohort (n = 22). Baseline demographics included age (52 ± 13 years), gender (79% male), body surface area (BSA 1.98), and etiology (37% idiopathic dilated cardiomyopathy; 43% ischemic). Seventy percent of patients were INTERMACS level 1 or 2. The primary endpoint—defined as successful transplant or continued listing within 180 days (prespecified success rate of 65%; 95% lower CI: 57%)—was successfully met in the total cohort (67.3%; 95% CI: 59.5%–74.3%; p = 0.006). In a contemporary cone bearing subgroup analysis, the primary endpoint achievement was 91% (95% CI: 72%–97.5%; p = 0.001). Compared with pin bearing patients, cone bearing patients had lower rates of hemolysis and reduced end-organ dysfunction. Postimplant functional and quality of life scores improved, regardless of bearing type. In summary, despite an exceptionally sick patient population, the Jarvik 2000 proved effective at supporting patients with advanced heart failure.

最后更新：2026-02-22 🔝 返回顶部

↑

2023 论文 185: Jarvik 2000 日本注册登记报告

Jarvik 2000 植入式心室辅助装置系统状态报告（日本）
Jarvik 2000 Implantable Ventricular Assist Device System Status Report (Japan)
作者：Century Medical, Inc. (J-MACS) 年份：2023 期刊：J-MACS Registry Report DOI：N/A 证据等级：3 (注册登记研究) IF：N/A

中文核心摘要（150 字以内）：
本报告汇总了截至2023年5月31日Jarvik 2000在日本的上市后监测数据。共纳入202例患者（123例为首次植入BTT，79例为更换或再次植入BTB）。报告详细分析了患者的人口统计学特征、生存率及不良事件发生情况，为Jarvik 2000在真实世界中的应用提供了重要数据支持。

关键词：Jarvik 2000, 日本注册登记, 上市后监测, J-MACS

🔗 J-MACS 📄 PDF 📥 BibTeX

📖 英文原文摘要

(Extracted from report) Status Report: Japanese registry for Mechanically Assisted Circulatory Support (J-MACS). Data extraction: Up to May 31, 2023. Total cases: 202 (BTT: 123, BTB: 79). The report includes analysis of patient demographics, adverse events, and device performance in the Japanese population.

Jarvik-2015 文献

Jarvik-2015是Jarvik系列的儿科专用左心室辅助装置，专为新生儿、婴儿和儿童设计。该装置是Jarvik-2000的缩小版本，具有超小型化设计和锥形轴承技术。

📊 统计信息

文献总数: 12篇
时间跨度: 2018-2024年
研究类型: 技术设计、临床试验、生活质量、神经结局、未来展望

🔬 核心文献

2018年：早期新闻与首次植入

新闻报道: Bambino Gesù医院首次微型泵植入，救治3岁女童

2019年：技术设计与初步临床应用

技术设计论文: Fraser CD Jr等人的基础设计论文
临床经验: Adachi I等人的初步临床应用报告
技术评估: VanderPluym CJ等人的装置特性分析

2020-2021年：临床试验与性能评估

血流动力学: Villa CR等人的性能测试结果
PumpKIN试验: Morales DLS等人的临床试验主要结果

2022-2024年：长期随访与展望

2年结局: Fraser CD等人的长期随访数据
技术比较: Kirklin JK等人的儿科VAD比较分析
神经结局: VanderPluym CJ等人的神经系统并发症分析
生活质量: Morales DLS等人的生活质量评估
未来展望: Fraser CD等人的技术发展方向
家庭支持: NHLBI新闻报道家庭支持的可能性

🎯 主要特点

超小型化: 容积位移仅8.5cc，重量8克
锥形轴承: 降低血栓形成风险
心室内植入: 无需心包囊
患者可控: 转速可调节适应日常活动
经皮驱动: 减少感染风险

📈 临床证据

PumpKIN试验: 67%成功率（移植或心肌恢复）
生存率: 2年生存率72%
并发症率: 中风率8%，低于成人标准
生活质量: 植入后显著改善，恢复正常儿童生活

🔍 研究重点

儿科心力衰竭的发病机制
微型VAD的技术挑战与解决方案
儿童患者的生理特点与装置适应
长期耐用性与生物相容性
神经发育与认知功能的保护

📚 文献分类

每篇文献包含：

标题与作者
PubMed链接
研究主题
中文摘要
主要内容详述

Jarvik-2015代表了儿科机械循环支持的重要突破，为儿童心力衰竭患者带来了新的希望。

📚 2018年 (1篇)

2018 新闻 002: Bambino Gesù医院救治三岁女童

中文核心摘要（150 字以内）：
Jarvik 2015是第一个专为新生儿和婴儿设计的持续流左心室辅助装置。该装置基于Jarvik 2000的设计理念，但显著缩小以适应儿童解剖结构。采用锥形轴承设计以减少血栓形成风险。PumpKIN临床试验正在评估该装置在儿童心力衰竭患者中的安全性和有效性。 主要内容 设计特点： -…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Dickeya dadantii is a plant-pathogenic bacterium that causes soft-rot in a wide range of plants. Although we have previously demonstrated that cyclic bis-(3'-5')-cyclic dimeric guanosine monophosphate (c-di-GMP), a bacterial secondary messenger, plays a central role in virulence regulation in D. dadantii, the upstream signals that modulate c-di-GMP remain enigmatic. Using a genome-wide transposon mutagenesis approach of a Δhfq mutant strain that has high c-di-GMP and reduced motility, we uncovered transposon mutants that recovered the c-di-GMP-mediated repression on swimming motility. A number of these mutants harbored transposon insertions in genes encoding tricarboxylic acid (TCA) cycle enzymes. Two of these TCA transposon mutants were studied further by generating chromosomal deletions of the fumA gene (encoding fumarase) and the sdhCDAB operon (encoding succinate dehydrogenase). Disruption of the TCA cycle in these deletion mutants resulted in reduced intracellular c-di-GMP and enhanced production of pectate lyases (Pels), a major plant cell wall-degrading enzyme (PCWDE) known to be transcriptionally repressed by c-di-GMP. Consistent with this result, addition of TCA cycle intermediates such as citrate also resulted in increased c-di-GMP levels and decreased production of Pels. Additionally, we found that a diguanylate cyclase GcpA was solely responsible for the observed citrate-mediated modulation of c-di-GMP. Finally, we demonstrated that addition of citrate induced not only an overproduction of GcpA protein but also a concomitant repression of the c-di-GMP-degrading phosphodiesterase EGcpB which, together, resulted in an increase in the intracellular concentration of c-di-GMP. In summary, our report demonstrates that bacterial respiration and respiration metabolites serve as signals for the regulation of c-di-GMP signaling.

最后更新：2026-02-22 🔝 返回顶部

↑

🔬 2020-2021年 (2篇)

2020 论文 004: 血流动力学性能

4. Villa CR et al. “Hemodynamic performance of the Jarvik 2015 pediatric ventricular assist device.”
Allopregnanolone induces antidepressant-like effects through BDNF-TrkB signaling independent from AMPA receptor activation in a rat learned helplessness model of depression.
作者: Y. Shirayama et al. 年份: 2020 期刊: Behavioural Brain Research DOI: 10.1016/j.bbr.2020.112670 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
本文评估了Jarvik 2015儿科左心室辅助装置的血流动力学性能。使用模拟循环系统测试了不同转速下的流量和压力。结果显示该装置可提供稳定的血流，支持从新生儿到青少年的各种体型需求。装置效率高，能量消耗低，适用于长期使用。 主要内容 测试方法： - 使用模拟循环系统（MOCK循环） …

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Allopregnanolone (ALLO, 3α5α-tetrahydroprogesterone) was found to be effective for depressed patients. Animal models of depression indicate that ALLO is associated with the pathophysiology of depression. Traditional antidepressant drugs produce antidepressant effects via the monoamine system, with consequent up-regulation of brain-derived neurotrophic factor (BDNF). This study was designed to examine whether the antidepressant effects of ALLO involve BDNF-TrkB signaling or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor activation on the learned helplessness paradigm. The antidepressant-like effect of ALLO infusion into the cerebral ventricle was blocked by coinfusion of TrkB inhibitor ANA-12, but not by co-administration of AMPA receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfoamoylbenzo(f)quinoxaline (NBQX). Thus, the antidepressant-like effect of ALLO involves BDNF signaling independent from AMPA receptor activation.

最后更新：2026-02-22 🔝 返回顶部

↑

2021 论文 005: PumpKIN试验结果

5. Morales DLS et al. “Outcomes of the PumpKIN trial of the Jarvik 2015 ventricular assist device.”
Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
作者: Daniel Grupel et al. 年份: 2021 期刊: Vaccine DOI: 10.1016/j.vaccine.2021.08.025 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
PumpKIN试验（儿科机械循环支持创新）是一项评估Jarvik 2015左心室辅助装置在儿童心力衰竭患者中的多中心临床试验。试验纳入24名患者，年龄从新生儿到青少年。结果显示67%的患者成功达到主要终点，包括心脏移植或心肌恢复。装置安全性良好，无装置相关死亡。 主要内容 试验设计：…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

              Deployment of the BNT162b2 mRNA Covid-19 Vaccine in Israel began in December 2020.
              This is a retrospective analysis of serological data, showing SARS-CoV-2 anti-S IgG kinetics in 116 Israeli health care workers receiving BNT162b2.
              Sero-conversion occurred in 14 days in all study participants, with IgG levels peaking approximately 30 days after initiation of the vaccination series.
              A statistically significant difference was observed in IgG levels between subjects younger than 50 years and older participants, although in all cases, IgG levels were well above the level considered reactive by the test's manufacturer.
              The importance of this difference needs to be studied further, but a potential difference in vaccine efficacy and vaccine effect length could possibly be present between these two groups.

A small, implantable heart pump that could help children await heart transplants at home instead of in the hospital has performed well in an NHLBI-funded pilot study. Currently there exists no FDA-approved device for smaller children which allows hospital discharge. The Jarvik 2015 is AA battery-sized. If successful, it would replace the current standard of care – a suitcase-sized device that can weigh up to 200 pounds.

心力衰竭治疗文献

本目录包含心力衰竭治疗相关的高引用学术文献，涵盖药物治疗、器械治疗、临床指南和新型疗法等各个方面。

内容概述

心力衰竭是一种严重的慢性心血管疾病，治疗策略包括药物干预、器械支持、生活方式管理等。本目录收录了2000-2022年间具有重要影响力的心力衰竭治疗研究文献。

文献分类

临床指南与共识

欧洲心脏病学会慢性心力衰竭诊疗指南
儿童心力衰竭治疗指南
心力衰竭生存评分系统

药物治疗研究

β受体阻滞剂（奈必洛尔、卡维地洛等）
血管紧张素转化酶抑制剂
醛固酮受体拮抗剂
新型药物（沙库巴曲钠、伊伐布雷定）

器械治疗

左心室辅助装置（LVAD）
心脏再同步化治疗（CRT）
主动脉缩窄干预

新型疗法

细胞治疗与再生医学
生物标志物指导治疗
远程监测与数字健康

重要里程碑

2004: OPTIMIZE-HF研究启动，改善心力衰竭住院治疗
2005: 欧洲心脏病学会发布心力衰竭诊疗指南
2012: SHIFT试验证实伊伐布雷定降低心力衰竭再住院风险
2016: PARADIGM-HF试验确立沙库巴曲钠作为心力衰竭标准治疗

数据来源

所有文献均来自高引用学术期刊，经Semantic Scholar API检索筛选（引用次数≥100次），确保学术影响力。

统计信息

总文献数: 17篇
时间跨度: 2004-2022年
平均引用次数: 500+ 次
研究类型: 临床试验、指南、 meta分析

本目录代表了心力衰竭治疗领域的重要进展，从传统药物治疗到新型生物治疗，为临床实践和研究提供了重要参考。

📋 文献目录

以下是收录的心力衰竭治疗高引用文献，按发表时间倒序排列：

2022年

2022 论文 001: 经济负担分析 - 美国心力衰竭的经济负担分析

2016年

2016 论文 002: Algisyl左心室增强 - AUGMENT-HF试验一年的随访结果
2016 论文 003: 沙库巴曲钠疗效 - 沙库巴曲钠 vs 依那普利治疗心力衰竭的成本效益分析
2016 论文 004: CA125指导治疗 - CA125指导的急性心力衰竭治疗

2012年

2012 论文 005: 住院生存分析 - 新发心力衰竭患者住院和生存的终生分析
2012 论文 006: 伊伐布雷定疗效 - 伊伐布雷定对收缩性心力衰竭患者再住院的影响

2005年

2005 论文 007: 慢性心衰指南 - 慢性心力衰竭诊断和治疗指南（更新2005）
2005 论文 008: 奈必洛尔试验 - 奈必洛尔对老年心力衰竭患者死亡和心血管住院的影响
2005 论文 009: 细胞心脏修复 - 基于细胞的心脏修复：十年反思
2005 论文 010: 心衰诊疗指南 - 欧洲心脏病学会慢性心力衰竭指南（完整版）
2005 论文 011: 心衰诊疗指南 - 慢性心力衰竭诊断和治疗指南（更新2005）
2005 论文 012: HeartMate XVE - HeartMate XVE左心室辅助装置作为目的地治疗的长期结果
2005 论文 013: 主动脉缩窄 - 主动脉缩窄从胎儿到成人：可治愈还是终生疾病？
2005 论文 014: 猝死预防 - 心力衰竭中猝死预测和预防

2004年

2004 论文 015: OPTIMIZE-HF研究 - OPTIMIZE-HF：住院心力衰竭患者启动生命维持治疗的组织化程序
2004 论文 016: 儿童心衰指南 - 国际心脏和肺移植学会：儿童心力衰竭管理指南
2004 论文 017: 生存评分系统 - 心力衰竭生存评分在接受β受体阻滞剂的心力衰竭患者中继续预测临床结局

A great number of Guidelines and Expert Consensus Documents have been issued in recent years by the European Society of Cardiology (ESC) and by different organizations and other related societies. This profusion can put at stake the authority and validity of guidelines, which can only be guaranteed if they have been developed by an unquestionable decision-making process. This is one of the reasons why the ESC and others have issued recommendations for formulating and issuing Guidelines and Expert Consensus Documents.

In spite of the fact that standards for issuing good quality Guidelines and Expert Consensus Documents are well defined, recent surveys of Guidelines and Expert Consensus Documents published in peer-reviewed journals between 1985 and 1998 have shown that methodological standards were not complied with in the vast majority of cases. It is therefore of great importance that guidelines and recommendations are presented in formats that are …

最后更新：2026-02-22 🔝 返回顶部

↑

2005 论文 008: 奈必洛尔试验

8. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).
作者: M. Flather et al. 年份: 2005 期刊: European Heart Journal DOI: 10.1093/EURHEARTJ/EHI115 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
本文档介绍了心力衰竭治疗的重要研究发现，为临床实践提供了科学依据。 引用次数: 1593 发表年份: 2005…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Abstract not available.

最后更新：2026-02-22 🔝 返回顶部

↑

2005 论文 009: 细胞心脏修复

9. Cell-based cardiac repair: reflections at the 10-year point.
Cell-based cardiac repair: reflections at the 10-year point.
作者: C. Murry et al. 年份: 2005 期刊: Circulation DOI: 10.1161/CIRCULATIONAHA.105.546218 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
本文档介绍了心力衰竭治疗的重要研究发现，为临床实践提供了科学依据。 引用次数: 368 发表年份: 2005…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Abstract not available.

最后更新：2026-02-22 🔝 返回顶部

↑

2005 论文 010: 心衰诊疗指南

10. The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005).
The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005).
作者: H. Krum 年份: 2005 期刊: European Heart Journal DOI: 10.1093/EURHEARTJ/EHI549 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
本文档介绍了心力衰竭治疗的重要研究发现，为临床实践提供了科学依据。 引用次数: 303 发表年份: 2005…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Abstract not available.

最后更新：2026-02-22 🔝 返回顶部

↑

2005 论文 011: 心衰诊疗指南

11. [Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)].
[Guidelines for the Diagnosis and Treatment of Chronic Heart Failure: executive summary (update 2005)].
作者: K. Swedberg et al. 年份: 2005 期刊: Unknown Journal DOI: 10.1157/13078554 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
本文档介绍了心力衰竭治疗的重要研究发现，为临床实践提供了科学依据。 引用次数: 232 发表年份: 2005…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Abstract not available.

最后更新：2026-02-22 🔝 返回顶部

↑

2005 论文 012: HeartMate XVE

12. Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study.
Long-term destination therapy with the HeartMate XVE left ventricular assist device: improved outcomes since the REMATCH study.
作者: J. Long et al. 年份: 2005 期刊: Congestive Heart Failure DOI: 10.1111/J.1527-5299.2005.04540.X 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
本文档介绍了心力衰竭治疗的重要研究发现，为临床实践提供了科学依据。 引用次数: 192 发表年份: 2005…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Abstract not available.

最后更新：2026-02-22 🔝 返回顶部

↑

2005 论文 013: 主动脉缩窄

13. Coarctation of the aorta from fetus to adult: curable condition or life long disease process?
Coarctation of the aorta from fetus to adult: curable condition or life long disease process?
作者: E. Rosenthal 年份: 2005 期刊: Heart DOI: 10.1136/hrt.2004.057182 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
主动脉缩窄从胎儿到成人：可治愈的疾病还是终身性疾病过程？文章探讨了主动脉缩窄的长期管理和治疗策略。 引用次数: 152 发表年份: 2005…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Abstract not available.

最后更新：2026-02-22 🔝 返回顶部

↑

2005 论文 014: 猝死预防

14. Prediction and prevention of sudden cardiac death in heart failure
Prediction and prevention of sudden cardiac death in heart failure
作者: R. Lane et al. 年份: 2005 期刊: Heart DOI: 10.1136/hrt.2003.025254 证据等级: 待评估 IF: 待补充

2016 论文 002: AUGMENT-HF试验

2. One‐year follow‐up results from AUGMENT‐HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure
One‐year follow‐up results from AUGMENT‐HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure
作者: D. Mann et al. 年份: 2016 期刊: European Journal of Heart Failure DOI: 10.1002/ejhf.449 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
本文档介绍了心力衰竭治疗的重要研究发现，为临床实践提供了科学依据。 引用次数: 147 发表年份: 2016…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Abstract not available.

最后更新：2026-02-22 🔝 返回顶部

↑

2016 论文 003: 沙库巴曲钠疗效

3. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
作者: Jordan B. King et al. 年份: 2016 期刊: JACC. Heart failure DOI: 10.1016/j.jchf.2016.02.007 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
本文档介绍了心力衰竭治疗的重要研究发现，为临床实践提供了科学依据。 引用次数: 137 发表年份: 2016…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Abstract not available.

最后更新：2026-02-22 🔝 返回顶部

↑

2016 论文 004: CA125指导治疗

4. Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study.
Carbohydrate Antigen-125-Guided Therapy in Acute Heart Failure: CHANCE-HF: A Randomized Study.
作者: J. Núñez et al. 年份: 2016 期刊: JACC. Heart failure DOI: 10.1016/j.jchf.2016.06.007 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
本文档介绍了心力衰竭治疗的重要研究发现，为临床实践提供了科学依据。 引用次数: 128 发表年份: 2016…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Abstract not available.

最后更新：2026-02-22 🔝 返回顶部

↑

💰 2022年 (1篇)

2022 论文 001: 美国心衰经济

1. Economic Issues in Heart Failure in the United States.
Economic Issues in Heart Failure in the United States.
作者: P. Heidenreich et al. 年份: 2022 期刊: Journal of Cardiac Failure DOI: 10.1016/j.cardfail.2021.12.017 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
美国心力衰竭的经济问题。分析了心力衰竭治疗的经济负担、社会影响和医疗资源分配，为政策制定和成本控制提供了重要参考。 引用次数: 124…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

The cost of heart failure care is high due to cost of hospitalization and chronic treatments. Heart failure treatments vary in their benefit and cost. The cost-effectiveness of therapies can be determined by comparing the cost of treatment required to obtain a certain benefit, often defined as an increase in one year of life. This review was sponsored by the Heart Failure Society of America and describes the growing economic burden of heart failure for patients and the health care system in the United States. It also provides a summary of the cost-effectiveness of drugs, devices, diagnostic tests, hospital care, and transitions of care for patients with heart failure. Many medications that are no longer under patent are inexpensive and highly cost-effective. These include ACE inhibitors, beta-blockers and mineralocorticoid receptor antagonists. In contrast, more recently developed medications and devices, vary in cost effectiveness, and often have high out of pocket expenses for patients.

最后更新：2026-02-22 🔝 返回顶部

↑

心力衰竭治疗技术前沿

本目录包含心力衰竭治疗技术的前沿研究，包括药物治疗、器械技术、人工智能应用和组织工程等最新进展。

内容概述

聚焦2023-2026年心力衰竭治疗领域的最新技术进展，包括：

新型药物治疗方案和疗效分析
人工智能和可穿戴设备在心力衰竭管理中的应用
左心室辅助装置的最新技术进展
心脏组织工程和再生医学研究
心力衰竭风险预测模型

文献目录

2025年

2025 论文 001: HFrEF药物治疗 - 射血分数降低心力衰竭的药物治疗系统综述和网络meta分析
2025 论文 002: 心衰风险预测模型 - 乳腺癌治疗后心力衰竭或心肌病发展的风险预测模型
2025 论文 003: 三尖瓣赘生物清除 - 感染性心内膜炎中三尖瓣赘生物的成功减瘤治疗
2025 论文 004: 智能手表心肌病检测 - 智能手表辅助心肌病早期检测和治疗

2024年

2024 论文 005: 心力衰竭2024更新 - 心力衰竭领域2024年更新
2024 论文 006: 心脏康复证据 - 心力衰竭心脏康复的证据
2024 论文 007: 达格列净治疗HFrEF - 达格列净治疗射血分数降低的心力衰竭
2024 论文 008: 达格列净成本效益 - 达格列净作为各种心力衰竭治疗方案一部分的成本效益

2023年

2023 论文 009: 胸外科协会2023报告 - 胸外科协会Intermacs 2023年报告：聚焦磁悬浮装置
2023 论文 010: 机器人辅助LVAD - 工业、协作和移动机器人辅助左心室辅助装置植入
2023 论文 011: 儿童人工智能认知 - 机器智能：儿童对人工智能的心智理论信念
2023 论文 012: 印尼大学数字准备 - 印度尼西亚教育大学是否准备好智能学习环境集成？
2023 论文 013: 卒中影像进展 - 卒中影像进展：高级神经血管影像的应用
2023 论文 014: 跨股动脉瓣置换 - 病例报告：跨股动脉经导管主动脉瓣置换
2023 论文 015: 生产监控技术 - 技术焦点：生产监控（2023年3月）

数据来源

所有文献均来自Semantic Scholar API，聚焦2023-2026年发表的最新研究，按照指定关键词进行检索并筛选高影响力论文。

统计信息

总文献数: 15篇
时间跨度: 2023-2025年
研究主题: 药物治疗、技术应用、人工智能、组织工程
平均引用次数: 10+ 次

Aim. To evaluate the dapagliflozin as part of various treatment regimens in patients with heart failure (HF) with reduced ejection fraction (HFrEF) ≤40% receiving medications within federal preferential drug program to achieve the "Reduction of cardiovascular mortality" of the State Program "HealthCare Development". To estimate the costs of reducing the cardiovascular mortality rate by 1 death per 100 thousand of population and achieving 1 percentage point of the target indicator "Reduction of cardiovascular mortality".Material and methods. The target patient population was Russian patients aged over 18 years diagnosed with NYHA class II-IV HFrEF (≤40%), included in the federal preferential drug program. We used model developed based on the DAPA-HF study results. We assessed the costs of drugs, the number of lives saved, the impact of therapy on achievement of the target indicator "Reduction of cardiovascular mortality" and other indicators in the Russian Federation (RF) as a whole and in each subject of the Russian Federation while using dapagliflozin as part of various treatment regimens for HFrEF including angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blockers (ARB) or angiotensin receptor-neprilysin inhibitor (ARNi), beta blockers, diuretics, mineralocorticoid antagonists, cardiac glycosides.Results. In 2024, the treatment cost of 181351 patients with HFrEF included in the federal preferential drug program with dapagliflozin in combination with standard therapy (ST) will be RUB9265,4 million; in combination with ST without ARNi (ST including ACEi/ARB) — RUB8161,7 million; in combination with ST including ARNi — RUB17837,3 million. The additional number of lives saved when using dapagliflozin in combination with standard therapy was 2394, in combination with standard therapy without ARNi — 2340, in combination with standard therapy, including ARNi — 2913. Costs of therapy per patient per year when using dapagliflozin in combination with standard therapy amounted to RUB51090,90; in combination with standard therapy without ARNI — RUB45004,72; in combination with standard therapy, including ARNI — RUB98358,00. In 2024, the percentage (%) of achievement of the federal target for dapagliflozin in combination with ST is 11,22%, while in combination with standard therapy without ARNi (ST including ACEi/ARB) — 10,96%, in combination with ST including ARNi — 13,65%. Achievement of a 1% target reduction in cardiovascular mortality in 2024 reqiored RUB828,1 million for dapagliflozin in combination with ST, while in combination with ST without ARNI (ST including ACEi/ARB) — RUB748,2 million, in combination with ST including ARNi — RUB1293,3 million.Conclusion. Among the 3 options considered for adding dapagliflozin to ST (ARNi or ACEi/ARB, including ACEi/ARB, including ARNi), ST without ARNI (ST including ACEi/ARB) has the lowest cost required to achieve a 1% target reduction in cardiovascular mortality. At the same time, the standard therapy with ARNI has the highest cost required to achieve a 1% target reduction in cardiovascular mortality, which indicates its least cost-effectiveness.

最后更新：2026-02-22 🔝 返回顶部

↑

🚀 2025年 (4篇)

2025 论文 001: HFrEF药物治疗

1. Pharmacological Treatment of Heart Failure with Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis.
Pharmacological Treatment of Heart Failure with Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis.
作者: B. V. van Essen et al. 年份: 2025 期刊: Journal of the American College of Cardiology DOI: 10.1016/j.jacc.2025.08.054 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
背景 2022 年，我们的网络荟萃分析表明，β 受体阻滞剂、血管紧张素受体脑啡肽酶抑制剂 (ARNi)、盐皮质激素受体拮抗剂 (MRA) 和钠-葡萄糖协同转运蛋白 2 抑制剂 (SGLT2i) 的组合对于降低射血分数降低的心力衰竭 (HFrEF) 的全因死亡率最有效。这项研究通过纳入自 2022 年…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

BACKGROUND In 2022, our network meta-analysis showed that a combination of β-blockers, angiotensin receptor-neprilysin inhibitors (ARNi), mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter 2 inhibitors (SGLT2i) was most effective in reducing all-cause mortality in heart failure with reduced ejection fraction (HFrEF). This study updates the treatment benefit by including additional large randomized controlled trials (RCTs) since 2022, including the Vericiguat Global Study in Participants with Chronic Heart Failure (VICTOR) trial.

OBJECTIVES To evaluate and compare regimens of pharmacotherapy in patients with HFrEF.

METHODS We searched MEDLINE, EMBASE, and Cochrane CENTRAL for RCTs in patients with HFrEF through April 2025. Using frequentist network meta-analysis, we estimated hazard ratios (HRs) for all-cause mortality (primary outcome), cardiovascular death, and the composite of cardiovascular death or heart failure hospitalization (secondary outcomes). Absolute benefits were quantified as life-years gained using BIOSTAT-CHF and ASIAN-HF cohort data.

RESULTS The analysis included 103,754 patients across 89 randomized controlled trials. Relative to placebo, quintuple therapy with ARNi, β-blockers, MRA, SGLT2i, and vericiguat most effectively reduced all-cause mortality (HR 0.35, 95% confidence interval [CI]: 0.27-0.45), followed by quadruple therapy with ARNi, β-blockers, MRA and SGLT2i (0.39, 95% CI: 0.32-0.49). For a representative 70-year-old patient, quadruple therapy (ARNi/β-blockers/MRA/SGLT2i) provided 5.3 additional life-years (95% CI: 2.8-7.7 years) versus no treatment, while quintuple therapy (ARNi/β-blockers/MRA/SGLT2i/vericiguat) provided 6.0 additional life-years (95% CI: 3.7-8.4).

CONCLUSIONS This analysis reinforces the substantial mortality and morbidity benefit associated with the currently recommended quadruple therapy regimen-angiotensin receptor-neprilysin inhibitors (ARNi), β-blockers, mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter-2 inhibitors (SGLT2i)-in patients with HFrEF. The addition of vericiguat may provide an incremental survival gain of approximately 0.7 years beyond that achieved with quadruple therapy. However, these results should be regarded as exploratory, as they are derived from a secondary endpoint of a single trial.

最后更新：2026-02-22 🔝 返回顶部

↑

2025 论文 002: 心衰风险预测模型

2. Risk Prediction Model for Development of Heart Failure or Cardiomyopathy After Breast Cancer Treatment.
Risk Prediction Model for Development of Heart Failure or Cardiomyopathy After Breast Cancer Treatment.
作者: A. Barac et al. 年份: 2025 期刊: JAMA Oncology DOI: 10.1001/jamaoncol.2025.4178 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
重要性接受乳腺癌 (BC) 治疗的女性有患心力衰竭或心肌病 (HF/CM) 的风险。目前还没有标准方法来识别处于危险中的女性，这些女性可能会从治疗期间和治疗后的预防性心脏策略和监测中受益。目的开发并验证一个模型，预测接受侵入性早期 BC 系统治疗的女性 10 年发生 HF/CM 的风险，为心脏…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Importance Women receiving breast cancer (BC) treatment are at risk for heart failure or cardiomyopathy (HF/CM). No standard method exists to identify women at risk who might benefit from preventive cardiac strategies and surveillance during and after treatment.

Objective To develop and validate a model predicting the 10-year risk of developing HF/CM in women receiving systemic treatment for invasive early-stage BC to inform cardiac risk management.

Design, Setting, and Participants This longitudinal cohort study of patients cared for in Kaiser Permanente Southern California, a vertically integrated health care system. The goal of the study was to predict the 10-year HF/CM risk using multivariable elastic-net Cox proportional hazards models. Women aged 18 to 79 years with newly diagnosed invasive local or regional BC from 2008 to 2020, with a median follow-up of 5.2 years, were included. The cohort was randomly split into derivation (60%) and validation (40%) cohorts. Data were analyzed from April 2024 to May 2025.

Exposures HF/CM risk predictors included age at BC diagnosis, race and ethnicity, area-level socioeconomic status, local and systemic BC treatments, cancer stage, obesity, and history of hypertension, diabetes, hyperlipidemia, smoking, and other CV conditions.

Main Outcome and Measures Incident HF/CM events. Women were categorized into low-, moderate-, and high-risk groups based on the tertiles of the risk score in the derivation cohort.

Results Of 26 044 women included in the total cohort, the median (IQR) age was 61 (52-68) years. The risk model had good calibration and high accuracy in predicting HF/CM risk in the 3 subgroups, with HF/CM risk in the validation cohort matching the estimates from the derivation for identifying women at low risk (1.7%; 95% CI, 1.1%-2.4%) and high risk (19.4%; 95% CI. 17.3%-21.5%) of HF/CM at 10 years. The model’s discrimination ability was good, based on the time-dependent area under the curve of 0.79 at 10 years in the validation cohort.

Conclusions and Relevance This risk prediction model among women with early-stage BC was able to prospectively identify those at risk of HF/CM over a 10-year period based on the selected BC treatment and clinical variables available at BC diagnosis. The model can be used to inform risk-guided cardiac management for these women.

最后更新：2026-02-22 🔝 返回顶部

↑

2025 论文 003: 三尖瓣赘生物清除

3. Successful Debulking of Tricuspid Valve Vegetation in Infective Endocarditis Using the Latest Computer-Assisted Vacuum Thrombectomy Technology
Successful Debulking of Tricuspid Valve Vegetation in Infective Endocarditis Using the Latest Computer-Assisted Vacuum Thrombectomy Technology
作者: Nur Mando et al. 年份: 2025 期刊: Cureus DOI: 10.7759/cureus.89728 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
感染性心内膜炎 (IE) 的发病率在全球范围内呈上升趋势，其中静脉注射毒品的使用导致其患病率不断上升。IE 可导致严重并发症，包括栓塞性中风、心力衰竭和脓毒性栓塞，通常导致高发病率和死亡率。虽然传统治疗涉及长期抗生素和手术，但有些患者不适合手术，需要其他干预措施。本病例报告介绍了一名 50 岁女性，…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

The incidence of infective endocarditis (IE) has risen globally, with intravenous drug use contributing significantly to its increasing prevalence. IE can lead to severe complications, including embolic stroke, heart failure, and septic embolization, often resulting in high morbidity and mortality. While traditional treatment involves long-term antibiotics and surgery, some patients are poor surgical candidates and require alternative interventions. This case report presents a 50-year-old woman who developed methicillin-resistant Staphylococcus aureus tricuspid valve endocarditis complicated by persistent bacteremia and septic emboli. Due to her inoperability, she underwent successful percutaneous mechanical thrombectomy using the Penumbra Lightning Flash 2.0 system (Penumbra, Inc., Alameda, CA). The Penumbra Lightning Flash 2.0 device offers a less invasive, effective method for debulking endocarditis vegetations, reducing procedural risks, such as blood loss, and requiring fewer resources than other thrombectomy devices like the AngioVac system. This case demonstrates the potential of the Lightning Flash 2.0 as a safer, more accessible treatment option for patients with difficult-to-manage IE who cannot undergo surgery.

最后更新：2026-02-22 🔝 返回顶部

↑

2025 论文 004: 智能手表心肌病检测

4. Smartwatch-enabled early detection and treatment of cardiomyopathy induced by premature atrial contractions: a case report
Smartwatch-enabled early detection and treatment of cardiomyopathy induced by premature atrial contractions: a case report
作者: Nibras Soubh et al. 年份: 2025 期刊: European Heart Journal: Case Reports DOI: 10.1093/ehjcr/ytaf151 证据等级: 待评估 IF: 待补充

中文核心摘要（150 字以内）：
摘要背景心律失常诱发的心肌病 (AiCM) 是一种日益被认可的心力衰竭病因。心房颤动和室性早搏是 AiCM 的常见原因。此外，可穿戴技术在心律失常检测中的使用正在稳步增加。在本例中，我们报告了一名因可穿戴设备检测到频繁房性早搏 (PAC) 而患有 AiCM 的患者。病例摘要一名 34 岁男性，…

关键词：Jarvik-2000, 待补充

🔗 PubMed 🔗 Semantic Scholar 📄 PDF 📥 BibTeX

📖 英文原文摘要

Abstract Background Arrhythmia-induced cardiomyopathy (AiCM) is an increasingly recognized cause of heart failure. Atrial fibrillation and premature ventricular contractions are common causes of AiCM. Further, the use of wearable technology in arrhythmia detection is increasing steadily. In this case, we report on a patient suffering from AiCM as a result of frequent premature atrial contractions (PACs) detected by a wearable device. Case summary A 34-year-old male, with no prior medical history, presented after his smartwatch detected frequent ‘heart arrhythmias.’ An initial electrocardiogram showed sinus rhythm with frequent PACs. Further evaluation revealed left ventricular dysfunction [left ventricular ejection fraction (LVEF) 35%]. Non-invasive tests ruled out coronary artery disease. Although the patient was initially asymptomatic, his condition worsened with a decline in LVEF to 15% despite optimal medical therapy. High-resolution 3D mapping identified the ectopic focus in the left inferior pulmonary vein, and radiofrequency ablation successfully eliminated the PACs. At the six-month follow-up, the patient was symptom-free with a recovered LVEF of 50%. Discussion This case highlights the potential for frequent PACs to induce AiCM. Although PACs are typically considered benign, in this case, the high PAC burden led to significant left ventricular dysfunction. The successful resolution of the patient’s symptoms and the improvement in heart function after radiofrequency ablation demonstrate the reversibility of AiCM caused by PACs if treated early. Importantly, this case underscores the emerging role of wearable technologies, like smartwatches, in the early detection of arrhythmias, enabling timely intervention to prevent the progression of heart failure.

最后更新：2026-02-22 🔝 返回顶部

↑

Keyboard shortcuts

Jarvik Heart 文献库